EYECARE: Coronavirus BRIEFING: Crisis Response Tactics FDA Advisers Consider Novavax COVID-19 Vaccine This Week By Staff Monday, June 6, 2022 6:00 AM The FDA’s vaccine advisors are scheduled to meet on Tuesday to consider authorizing the Novavax COVID-19 vaccine.The committee will vote on whether the benefits of the two-dose vaccine outweigh the risks for ages 18 and older, according to the 80-page briefing document posted Friday.Based on data included in the document, an FDA review found that the vaccine’s effectiveness was 90.4 percent overall against mild, moderate, or severe COVID-19 for about 2.5 months after completing the two doses. For adults 65 and older, effectiveness fell to 78.6 percent. Head over to WebMD to read the full story.